TDMS Study 50215-03 Pathology Tables
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
MICE FINAL#1
Facility: Battelle Columbus Laboratory
Chemical CAS #: 107-13-1
Lock Date: 11/03/99
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 6 15 10 25
Moribund Sacrifice 5 3 1 1
Dosing Accident 1
Survivors
Terminal Sacrifice 39 32 39 22
Moribund Sacrifice 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Leiomyosarcoma 1 (2%)
Intestine Large, Rectum (50) (50) (49) (50)
Intestine Large, Cecum (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Duodenum (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Jejunum (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Ileum (50) (50) (50) (50)
Liver (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangiosarcoma 2 (4%) 1 (2%) 1 (2%)
Hepatocellular Carcinoma 7 (14%) 3 (6%) 6 (12%) 2 (4%)
Hepatocellular Adenoma 8 (16%) 10 (20%) 10 (20%) 9 (18%)
Hepatocellular Adenoma, Multiple 6 (12%) 4 (8%) 5 (10%) 1 (2%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lipoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%) 1 (2%) 7 (14%)
Mesentery (9) (10) (10) (10)
Fibrosarcoma, Metastatic, Skin 1 (10%)
Hemangiosarcoma 1 (11%) 1 (10%)
Page 2
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Sarcoma 1 (10%)
Sarcoma, Metastatic, Skin 1 (11%) 1 (10%)
Fat, Squamous Cell Carcinoma, Metastatic,
Stomach, Forestomach 2 (20%)
Pancreas (50) (50) (50) (50)
Sarcoma, Metastatic, Skin 1 (2%)
Salivary Glands (50) (50) (49) (50)
Sarcoma, Metastatic, Skin 1 (2%)
Stomach, Forestomach (50) (50) (50) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma 1 (2%) 1 (2%) 11 (22%)
Squamous Cell Papilloma 2 (4%) 6 (12%) 20 (40%) 10 (20%)
Squamous Cell Papilloma, Multiple 1 (2%) 4 (8%) 9 (18%)
Stomach, Glandular (50) (50) (50) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 3 (6%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Bilateral, Histiocytic Sarcoma 1 (2%)
Subcapsular, Adenoma, Multiple 1 (2%)
Adrenal Medulla (50) (50) (50) (50)
Pheochromocytoma Benign 1 (2%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (50) (50) (50)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (48) (49) (48) (49)
Meningioma Malignant, Metastatic, Brain 1 (2%)
Pars Distalis, Adenoma 2 (4%) 4 (8%) 4 (8%) 2 (4%)
Page 3
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Thyroid Gland (50) (50) (49) (50)
Follicular Cell, Adenoma 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (48) (49) (48)
Ovary (50) (50) (50) (50)
Cystadenoma 8 (16%) 4 (8%) 2 (4%) 3 (6%)
Granulosa Cell Tumor Malignant 1 (2%)
Granulosa Cell Tumor Benign 3 (6%) 1 (2%)
Hemangioma 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Luteoma 1 (2%)
Oviduct (1) (1)
Uterus (50) (50) (50) (50)
Hemangioma 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Leiomyoma 1 (2%)
Polyp Stromal 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Lymph Node (37) (32) (30) (25)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (3%)
Mediastinal, Histiocytic Sarcoma 1 (3%)
Mediastinal, Liposarcoma, Metastatic, Skin 1 (3%)
Mediastinal, Sarcoma, Metastatic, Mesentery 1 (3%)
Pancreatic, Histiocytic Sarcoma 1 (3%)
Lymph Node, Mandibular (49) (49) (47) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (50) (49) (50) (47)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Page 4
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lung 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Spleen (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Thymus (50) (50) (47) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Carcinoma 1 (2%)
Fibroadenoma 1 (2%)
Skin (50) (50) (50) (50)
Basal Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Alveolar/Bronchiolar
Carcinoma, Metastatic, Lung 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 2 (4%) 2 (4%) 3 (6%) 2 (4%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (3) (3) (2) (1)
Histiocytic Sarcoma 1 (33%)
Sarcoma, Metastatic, Mesentery 1 (50%)
Sarcoma, Metastatic, Skin 1 (33%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Meningioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 4 (8%) 1 (2%) 8 (16%) 5 (10%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 5 (10%) 6 (12%) 4 (8%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Basal Cell Carcinoma, Metastatic, Skin 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 3 (6%) 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%) 1 (2%)
Bronchus, Adenoma 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%) 1 (2%)
Mediastinum, Fibrosarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Sarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Nose (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (49) (50) (49) (49)
Adenoma 8 (16%) 10 (20%) 21 (43%) 19 (39%)
Carcinoma 1 (2%) 3 (6%) 2 (4%)
Bilateral, Adenoma 2 (4%) 4 (8%) 4 (8%)
Zymbal's Gland (1)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 6
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Capsule, Squamous Cell Carcinoma, Metastatic,
Stomach, Forestomach 1 (2%)
Renal Tubule, Adenoma 1 (2%) 1 (2%) 1 (2%)
Urinary Bladder (50) (49) (50) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant 4 (8%) 5 (10%) 7 (14%) 6 (12%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 7
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 39 41 50 40
Total Primary Neoplasms 68 71 123 99
Total Animals with Benign Neoplasms 29 33 45 33
Total Benign Neoplasms 44 48 89 70
Total Animals with Malignant Neoplasms 24 22 30 24
Total Malignant Neoplasms 24 23 34 29
Total Animals with Metastatic Neoplasms 4 5 10 12
Total Metastatic Neoplasm 11 10 21 26
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 11 3 8 32
Moribund Sacrifice 1 3 3 4
Dosing Accident 2
Survivors
Terminal Sacrifice 38 42 39 14
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (50) (49) (50) (48)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Intestine Large, Colon (50) (50) (50) (50)
Intestine Small, Duodenum (50) (50) (50) (50)
Polyp Adenomatous 1 (2%) 3 (6%)
Intestine Small, Jejunum (50) (50) (50) (50)
Carcinoma 2 (4%) 1 (2%)
Intestine Small, Ileum (50) (50) (50) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Liver (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Hemangiosarcoma, Multiple 1 (2%) 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 11 (22%) 9 (18%) 13 (26%) 6 (12%)
Hepatocellular Carcinoma, Multiple 3 (6%) 1 (2%) 4 (8%)
Hepatocellular Adenoma 13 (26%) 21 (42%) 11 (22%) 10 (20%)
Hepatocellular Adenoma, Multiple 10 (20%) 11 (22%) 18 (36%) 4 (8%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 4 (8%) 4 (8%)
Mesentery (8) (6) (8) (3)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (17%)
Page 9
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Hemangioma 1 (17%)
Sarcoma 1 (13%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (13%)
Fat, Carcinoma, Metastatic, Harderian Gland 1 (13%)
Fat, Squamous Cell Carcinoma, Metastatic,
Stomach, Forestomach 2 (25%) 2 (67%)
Pancreas (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 3 (6%) 2 (4%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (50) (50) (50)
Squamous Cell Carcinoma 8 (16%) 9 (18%)
Squamous Cell Papilloma 3 (6%) 4 (8%) 17 (34%) 16 (32%)
Squamous Cell Papilloma, Multiple 2 (4%) 9 (18%)
Stomach, Glandular (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 3 (6%) 2 (4%)
Tongue (2)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (50%)
Squamous Cell Carcinoma 1 (50%)
Tooth (9) (5) (4) (3)
Peridontal Tissue, Sarcoma 1 (33%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Schwannoma Malignant 1 (2%)
Pericardium, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Adenoma 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Subcapsular, Adenoma 3 (6%) 3 (6%)
Adrenal Medulla (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%)
Islets, Pancreatic (50) (50) (50) (50)
Adenoma 2 (4%) 2 (4%)
Pituitary Gland (49) (46) (47) (47)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (50) (50) (50)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (1) (2)
Epididymis (50) (50) (50) (50)
Sarcoma, Metastatic, Mesentery 1 (2%)
Preputial Gland (49) (50) (50) (50)
Hemangioma 1 (2%)
Prostate (50) (50) (50) (50)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Seminal Vesicle (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Testes (50) (50) (50) (50)
Page 11
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Interstitial Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 2 (4%)
Lymph Node (6) (4) (6) (5)
Bronchial, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 1 (20%)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (17%) 1 (25%) 1 (17%) 1 (20%)
Mediastinal, Carcinoma, Metastatic,
Harderian Gland 1 (17%)
Mediastinal, Hepatocellular Carcinoma,
Metastatic, Liver 1 (17%)
Mediastinal, Sarcoma, Metastatic, Mesentery 1 (17%)
Mediastinal, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 1 (17%)
Pancreatic, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 1 (17%) 1 (20%)
Renal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (25%)
Lymph Node, Mandibular (49) (47) (47) (47)
Lymph Node, Mesenteric (48) (48) (49) (48)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangioma 2 (4%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 2 (4%)
Spleen (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Thymus (47) (47) (44) (46)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
Page 12
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteosarcoma 1 (2%) 1 (2%)
Osteosarcoma, Multiple 1 (2%)
Femur, Fibrosarcoma 1 (2%)
Skeletal Muscle (1) (2)
Carcinoma, Metastatic, Stomach, Forestomach 1 (50%)
Sarcoma, Metastatic, Mesentery 1 (100%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 10 (20%) 8 (16%) 4 (8%) 6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 4 (8%) 2 (4%) 4 (8%) 2 (4%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 2 (4%) 2 (4%) 2 (4%)
Carcinoma, Metastatic, Harderian Gland 3 (6%) 1 (2%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 5 (10%) 3 (6%) 4 (8%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 4 (8%) 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%) 1 (2%) 1 (2%)
Mediastinum, Hepatocellular Carcinoma,
Page 13
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Metastatic, Liver 1 (2%)
Mediastinum, Osteosarcoma, Metastatic, Bone 1 (2%)
Nose (50) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (50) (50) (50) (50)
Adenoma 5 (10%) 16 (32%) 15 (30%) 21 (42%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma 1 (2%) 1 (2%) 4 (8%) 3 (6%)
Bilateral, Adenoma 9 (18%) 6 (12%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 2 (4%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%) 1 (2%)
Capsule, Carcinoma, Metastatic, Harderian
Gland 1 (2%)
Capsule, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
Renal Tubule, Adenoma 1 (2%) 1 (2%) 1 (2%)
Urinary Bladder (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant 3 (6%) 3 (6%) 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 14
NTP Experiment-Test: 50215-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ACRYLONITRILE Date: 10/31/00
Route: GAVAGE Time: 12:42:06
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 2.5 10 MG/KG 20 MG/KG
MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 45 43 49 41
Total Primary Neoplasms 85 92 125 106
Total Animals with Benign Neoplasms 34 39 45 39
Total Benign Neoplasms 51 69 86 76
Total Animals with Malignant Neoplasms 29 18 30 24
Total Malignant Neoplasms 34 23 39 30
Total Animals with Metastatic Neoplasms 8 7 13 9
Total Metastatic Neoplasm 19 19 47 30
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 15
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------